This shared resource supports 2 functions: patient sample repository and specialized flow cytometry. The repository functions of the core include the acquisition of appropriate patient samples, isolation and cryopreservation of mononuclear cells, separation and storage of plasma or serum, maintenance of a database annotating patient samples and distribution of samples to program investigators. We will safeguard patient privacy by ensuring that all samples are de-identified and are assigned coded unique identifying numbers. We will also verify compliance with our internal regulatory policies which stipulate that samples may be obtained and studied only from patients who have signed an IRB approved informed consent document. The flow cytometry functions of the core include multiparameter analysis of heterogeneous samples and high-speed cell sorting to obtain highly purified populations of defined progenitor populations.
The specific aims of this core are listed below: 1. To ensure the maintenance of patient privacy and to verify that informed consent has been obtained for acquisition and study of all samples. 2. To ensure the acquisition of appropriate samples as designated in clinical research protocols carried out by program investigators. 3. To isolate and cryopreserve mononuclear cells and plasma or serum components from patient samples for subsequent study by program investigators. 4. To maintain an annotated database containing pathologic, cytogenetic and molecular information for clinical samples obtained from patients with myeloid leukemias. 5. To ensure that samples are distributed in a timely and equitable fashion to laboratory investigators for experiments proposed in this application. 6. To provide specialized multi-parameter analysis and high-speed cell sorting to obtain highly purified populations for functional and genetic analysis

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-15
Application #
8377892
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
2014-03-30
Budget Start
2012-04-01
Budget End
2013-03-30
Support Year
15
Fiscal Year
2012
Total Cost
$178,441
Indirect Cost
$58,878
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:

Showing the most recent 10 out of 376 publications